Oral Combination Treatment of Gefitinib (IressaTM) and Sasam-Kyeongokgo: Synergistic Effects on the NCI-H520 Tumor Cell Line
Source abstract
Abstract
The aim of this research was to confirm the possible synergic effects of sasam-Kyeongokgo (SKOG) on the anti-tumor activity of gefitinib using athymic nude mice bearing the human non-small-cell lung squamous cell carcinoma (NSCLC) NCI-H520 cell line after continuous oral combination treatment provided daily for 35 days within a timeframe of 5 min, as a developing process of novel preventive and therapeutic regimes for various types of lung cancer. After 35 days, BW, tumor volume and weight, and lymphatic and periovarian fat pad weight measurements, as well as serum IFN-γ and IL-6 level, NK cell activity, and splenic cytokine content measurements, together with histopathological observations, and immunohistochemistry measurements of the treated and control mice, were performed. The results suggest that the co-administration of SKOG 400, 200, or 100 mg/kg with gefitinib markedly increased the anti-tumor activity of gefitinib through immunostimulatory effects and also dramatically inhibited cancer cachexia through the immunostimulatory effect, potentiating the anti-tumor activity of gefitinib, with favorable anti-cachexia effects. Therefore, the co-administration of over 100 mg/kg of SKOG and gefitinib can provide an effective novel treatment regimen for various lung cancer patients.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Lung Cancer Treatments and Mutations · Cancer, Hypoxia, and Metabolism · Ginseng Biological Effects and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Histology and Anatomy, College of Korean Medicine, Daegu Haany University, Gyeongsan-si 38610, Republic of Korea
Department of Companion Animal Health, Daegu Haany University, Gyeongsan-si 38610, Republic of Korea
Research Institute, Okchundang Inc., Daegu 41059, Republic of Korea
Department of Seafood Science and Technology, The Institute of Marine Industry, Gyeongsang National University, 38 Cheondaegukchi-gil, Tongyeong-si 53064, Republic of Korea
References (65)
Show source-provided references
1. Rossi, S. (2004). Australian Medicines Handbook 2004, Australian Medicines Handbook Pty Ltd.
2. Common side effects of anti-EGFR therapy: Acneform rash10.1016/j.soncn.2006.01.013 ↗
3. Protective effects of lupeol against D-galactosamine and lipopolysaccharide-induced fulminant hepatic failure in mice10.1021/np500296b ↗
4. Structure of methyl adenophorate and triphyllol, triterpenoids of Adenophora triphylla var. japonica roots10.1055/s-2007-971639 ↗
5. Roots extracts of Adenophora triphylla var. japonica improve obesity in 3T3-L1 adipocytes and high-fat diet-induced obese mice10.1016/j.apjtm.2015.10.011 ↗
6. Lupenone isolated from Adenophora triphylla var. japonica extract inhibits adipogenic differentiation through the downregulation of PPARγ in 3T3-L1 cells10.1002/ptr.4779 ↗
7. Separation of two cytotoxic saponins from the roots of Adenophora triphylla var. japonica by high-speed counter-current chromatography10.1002/pca.2394 ↗
8. Effects of lupenone, lupeol, and taraxerol derived from Adenophora triphylla on the gene expression and production of airway MUC5AC mucin10.4046/trd.2015.78.3.210 ↗
9. Antitussive, expectorant, and anti-inflammatory effects of Adenophorae Radix powder in ICR mice10.1016/j.jep.2019.111915 ↗
10. Effects of Kyeongok-go and its two added precriptions on hyperlipidemic rats induced by high-fat diet
11. Effect of original Kyungokgo & Iksuyongjingo plus Sparassis crispa on antioxidant, immunity improvement and sensory evaluation10.6116/kjh.2016.31.4.43. ↗
12. Qualities and anti-inflammatory activity of Kyungokgos sold in local markets10.3746/jkfn.2013.42.3.335 ↗
13. Inhibitory effects on bone resorption and osteoblast proliferation of Kyungok-go
14. The effect of Gyungokgo-gamibang extract on hair growth and protein expression in mice
15. Effect of Kyungohkgo on aerobic capacity and anti-fatigue in high school soccer players
16. A comparative study on effects of Kyungohkgo and Kyungohkgo Ga Nokyong on growth in growth deficiency rat with insufficient nutrition diet
17. Effects of Kyunohkgo on antioxidant capacity in D-galactose induced aging rats
18. Experimental studies of the effects of Kyungok-go against Mycobacteria tuberculosis
19. Anti-inflammatory, expectorant, and antitussive properties of Kyeongok-go in ICR mice10.1080/13880209.2021.1892155 ↗
20. Hu, J.R., Jung, C.J., Ku, S.M., Jung, D.H., Ku, S.K., Bashir, K.M.I., Lee, H.J., and Choi, J.S. (2021). Deciphering the antitussive, expectorant, and anti-inflammatory potentials of ShashamKyeongok-go and their phytochemical attributes: In vivo appraisal in ICR mice. Appl. Sci., 11.10.3390/app11031349 ↗
21. Lee, J.Y., Lee, Y.M., Chang, G.C., Yu, S.L., Hsieh, W.Y., Chen, J.J., Chen, H.W., and Yang, P.C. (2011). Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: The versatile adjuvant for gefitinib therapy. PLoS ONE, 6.10.1371/journal.pone.0023756 ↗
22. In vivo and in vitro antitumor effects of platycodin d, a saponin purified from platycodi radix on the h520 lung cancer cell10.1155/2014/478653 ↗
23. Combination of NIR therapy and regulatory T cell modulation using layer-by-layer hybrid nanoparticles for effective cancer photoimmunotherapy10.7150/thno.26758 ↗
24. Plug-and-Play continuous gas flow assembly of cysteine-inserted AuCu nanobimetals for folate-receptor-targeted chemo-phototherapy10.1021/acsami.9b02330 ↗
25. Immunomodulatory effects of Kuseonwangdogo-Based mixed herbal formula extracts on a cyclophosphamide-induced immunosuppression mouse model10.1155/2018/6017412 ↗
26. Phellinus baumii enhances the immune response in cyclophosphamide-induced immunosuppressed mice10.1016/j.nutres.2019.12.005 ↗
27. Anticachectic effects of Coptidis rhizoma, an anti-inflammatory herb, on esophageal cancer cells that produce interleukin 610.1016/S0304-3835(00)00496-1 ↗
28. Medroxyprogesterone acetate inhibits interleukin 6 secretion from KPL-4 human breast cancer cells both in vitro and in vivo: A possible mechanism of the anticachectic effect10.1038/sj.bjc.6690099 ↗
29. Update: Microcomputer statistics packages. A personal view10.1111/j.1440-1681.1997.tb01823.x ↗
30. Blood glycemia-modulating effects of melanian snail protein hydrolysates in mice with type II diabetes10.3892/ijmm.2017.2967 ↗
31. Gefitinib in non small cell lung cancer
32. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: A systematic review10.1016/j.drup.2011.02.004 ↗
33. AstraZeneca Pharmaceuticals (2005). Iressa (Gefitinib) Tablets Prescribing Information, AstraZeneca.
34. Exfoliative eruption secondary to gefitinib (ZD1839)10.1159/000106590 ↗
35. Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: Implications for pulmonary and hepatic toxicities10.1021/tx900256y ↗
36. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib10.1056/NEJMoa044238 ↗
37. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer10.1158/1078-0432.CCR-07-2248 ↗
38. Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro10.1002/ijc.20917 ↗
39. Synergistic anticancer effects of combined γ-tocotrienol with statin or receptor tyrosine kinase inhibitor treatment10.1007/s12263-011-0225-y ↗
40. Growth inhibition of non-small cell lung cancer cells by AP-1 blockade using a cJun dominant-negative mutant10.1038/sj.bjc.6604267 ↗
41. Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects10.1016/j.biopha.2009.06.010 ↗
42. Concurrent hormone and radiation therapy in patients with breast cancer: What is the rationale?10.1016/S1470-2045(08)70333-4 ↗
43. Development of chondrosarcoma animal models for assessment of adjuvant therapy10.1111/j.1445-2197.2009.04884.x ↗
44. Clinical and experimental study on regional administration of phosphorus 32 glass microspheres in treating hepatic carcinoma10.3748/wjg.v5.i6.492 ↗
45. An antioxidant, probucol, induces anti-angiogenesis and apoptosis in athymic nude mouse xenografted human head and neck squamous carcinoma cells10.1111/j.1349-7006.1999.tb00700.x ↗
46. Where have all the T cells gone? Mechanisms of immune evasion by tumors10.1016/S0167-5699(98)01435-2 ↗
47. Escape mechanisms in tumor immunity: A year 2000 update
48. Anti-metastatic activity of glycoprotein fractionated from Acanthpanax senticosus, involvement of NK-cell and macrophage activation10.1007/BF02980109 ↗
49. In vitro effect of Yuza (Citrus junos SIEB ex TANAKA) extracts on proliferation of human prostate cancer cells and antioxidant activity
50. Anticancer effects of garlic and garlic-derived compounds for breast cancer control10.2174/187152011795347441 ↗
51. Tumor necrosis factor promotes human T-cell development in nonobese diabetic/severe combined immunodeficient mice10.1634/stemcells.22-6-1085 ↗
52. Tizard, I.R. (1995). Lymphokines and Cytokines. Immunology an Introduction, Saunders. [4th ed.].
53. Tizard, I.R. (1995). The Mononuclear-Phagocytic Sytem. Immunology an Introduction, Saunders. [4th ed.].
54. Advances in cytochemical methods for detection of apoptosis10.1177/002215540104900703 ↗
55. Fang, E.F., Zhang, C.Z., Zhang, L., Wong, J.H., Chan, Y.S., Pan, W.L., Dan, X.L., Yin, C.M., Cho, C.H., and Ng, T.B. (2012). Trichosanthin inhibits breast cancer cell proliferation in both cell lines and nude mice by promotion of apoptosis. PLoS ONE, 7.10.1371/journal.pone.0041592 ↗
56. Mediators of PGE2 synthesis and signaling downstream of COX-2 represent potential targets for the prevention/treatment of colorectal cancer
57. Alterations in nitric oxide production in various forms of circulatory shock
58. Selective pharmacological inhibition of distinct nitric oxide synthase isoforms10.1016/0006-2952(95)02099-3 ↗
59. The role of tumour-derived iNOS in tumour progression and angiogenesis10.1038/sj.bjc.6606034 ↗
60. Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells10.1084/jem.181.4.1333 ↗
61. Luteolin enhances TNF-related apoptosis-inducing ligand’s anticancer activity in a lung cancer xenograft mouse model10.1016/j.bbrc.2011.12.055 ↗
62. Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma
63. Cancer anorexia-cachexia syndrome: Are neuropeptides the key?
64. Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adenocarcinoma-bearing mice with modulation of lysosomal and ATP-ubiquitin-dependent proteolytic pathways10.1002/(SICI)1097-0215(19961127)68:5<637::AID-IJC14>3.0.CO;2-Z ↗
65. EGFR regulation by microRNA in lung cancer: Correlation with clinical response and survival to gefitinib and EGFR expression in cell lines10.1093/annonc/mdn006 ↗